Science Bulletin, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 1, 2024
Language: Английский
Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 94, P. 102203 - 102203
Published: Jan. 20, 2024
Language: Английский
Citations
48
Ageing Research Reviews, Journal Year: 2023, Volume and Issue: 91, P. 102044 - 102044
Published: Aug. 28, 2023
According to the Geroscience concept that organismal aging and age-associated diseases share same basic molecular mechanisms, identification of biomarkers age can efficiently classify people as biologically older (or younger) than their chronological (i.e. calendar) is becoming paramount importance. These will be in fact at higher lower) risk for many different diseases, including cardiovascular neurodegeneration, cancer, etc. In turn, patients suffering from these are healthy age-matched individuals. Many correlate with have been described so far. The aim present review discuss usefulness some (especially soluble, circulating ones) order identify frail patients, possibly before appearance clinical symptoms, well diseases. An overview selected discussed this regard, particular we focus on related metabolic stress response, inflammation, cell death (in neurodegeneration), all phenomena connected inflammaging (chronic, low-grade, inflammation). second part review, next-generation markers such extracellular vesicles cargos, epigenetic gut microbiota composition, discussed. Since recent progresses omics techniques allowed an exponential increase production laboratory data also field age, making it difficult extract biological meaning huge mass available data, Artificial Intelligence (AI) approaches increasingly important strategy extracting knowledge raw providing practitioners actionable information treat patients.
Language: Английский
Citations
28
Frontiers in Aging Neuroscience, Journal Year: 2025, Volume and Issue: 16
Published: Jan. 29, 2025
Objective The aim of this study was to compare the efficacy and safety anti-tau protein monoclonal antibodies for Alzheimer’s disease (AD). Tau aggregation, a key pathological feature AD, is closely associated with neurodegeneration cognitive decline. Targeting tau has emerged as promising therapeutic strategy. By investigating effects on function, progression, overall quality life in patients which can provide valuable insights into their potential option devastating neurodegenerative disorder. Methods randomized controlled trials (RCTs) Gosuranemab, Semorinemab, Tilavonemab, Zagotenemab (AD) were systematically searched across PubMed, Embase, Web Science Cochrane Library, up May 2024. control group included placebo. indicators change Mini Mental State Examination (MMSE), Clinical Dementia Rating Scale Sum Boxes (CDR-SB), Disease Assessment Scale-Cognitive (ADAS-Cog), Cooperative Study-Activities Daily Living (ADCS-ADL) from baseline until time observation. Statistical analysis conducted using Stata 14 RevMan 5.4. purpose data processing, including generating network evidence plots, surface under cumulative ranking curve (SUCRA) ranking, league funnel visually summarize evaluate relative effectiveness publication bias multiple interventions. Mean differences (MD) 95% confidence interval (95%CI) effect sizes analyze continuous variables. Results This encompassed six RCTs involving 2,193 patients. Semorinemab more effective than placebo MMSE ADAS-Cog scores (MDs ranging between 0.52 3.21; MDs 0.17 3.30). Placebo showed relatively good according SUCRA CDR-SB ADCS-ADL (75.7 79.5%). Tilavonemab exhibited similar that two indicators. lower incidence AE, SAE, fall, urinary tract infections placebo, statistically significant. Most results no statistical difference. Conclusion indicated antibodies, such promise terms managing AD. Further studies are needed confirm these findings, assess long-term effects, refine treatment protocols. Systematic review registration https://www.crd.york.ac.uk/prospero/#myprospero , CRD42024583388.
Language: Английский
Citations
1
JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(2), P. e2459170 - e2459170
Published: Feb. 26, 2025
Importance Given the increasing prevalence of dementia and limited treatment options available, ultrasound neuromodulation could serve as a novel add-on therapy to standard treatments for Alzheimer disease (AD). As is still in its early stages, further research essential fully explore potential treating brain disorders. Objective To evaluate clinical functional imaging effects transcranial pulse stimulation (TPS) patients with AD. Design, Setting, Participants A randomized, double-blind, sham-controlled, crossover trial was conducted at Medical University Vienna between January 1, 2017, July 27, 2022. Sixty clinically diagnosed AD receiving state-of-the-art were randomly allocated sequence groups verum-sham (first cycle verum, second sham, n = 30) sham-verum (n 30). Data analysis performed from 28, 2022, September 5, 2024. Intervention Each participant received 6 verum sham TPS sessions (6000 pulses, 0.20 mJ/mm 2 , 5 Hz) frontoparietal areas. Main Outcomes Measures Neuropsychological tests, including primary outcome Consortium Establish Registry Alzheimer’s Disease (CERAD) corrected total score (CTS), baseline 1 week, month, 3 months following stimulations each cycle. Primary secondary outcomes, magnetic resonance Beck Depression Inventory-II, analyzed by intention-to-treat and, sensitivity, per protocol analysis. Results For analysis, 60 ages 51 82 years (mean [SD], 70.65 [8.16] years; 30 females; males) included. The CERAD CTS increased mean (SD) 2.22 (6.87) points condition 70.93 (14.27) 73.15 (14.90) after stimulation, while 1.00 (6.82) point vs 71.68 (13.62] 72.68 (14.48) stimulation. data × session interaction not significant ( P .68; partial η [ηp ] 0.01), but age .003; ηp 0.08, followed post hoc analyses subsamples. Although several older than 70 benefited TPS, only younger subgroup (≤70 years) showed significantly higher increases all poststimulation (condition session: .005; 0.16). At example, 3.91 (7.86)-point increase found patients, decrease 1.83 (5.80) observed sham. Memory-associated activation precuneus, visual, frontal areas, resting state connectivity upregulated dorsal attention network. In sample, reduction Inventory-II scores (verum baseline: 7.27 [5.87]; stimulation: 5.27 [5.27]; 6.70 [5.65]; 6.22 [4.40]; .008; 0.23). During both conditions, most common adverse symptom depression; no major neuropathologic change detected detailed neuroradiologic assessments. Conclusions Relevance this randomized AD, 2-week improved cognitive subgroup, ameliorated depressive symptoms, induced upregulation connectivity. These findings suggest may be safe promising treatment. Trial Registration ClinicalTrials.gov Identifier: NCT03770182
Language: Английский
Citations
1
International Journal of Nanomedicine, Journal Year: 2023, Volume and Issue: Volume 18, P. 7825 - 7845
Published: Dec. 1, 2023
Abstract: Recent successive approval of anti-amyloid-β (Aβ) monoclonal antibodies as disease-modifying therapies against Alzheimer's disease (AD) has raised great confidence in the development anti-AD therapies; however, current still face dilemma significant adverse reactions and limited effects. In this review, we summarized therapeutic characteristics approved anti-Aβ immunotherapies dialectically analyzed gains losses from clinical trials. The review further proposed reasonable selection animal models preclinical studies perspective different Aβ deposition deals in-depth with recent advances exploring nanomedical application targeted therapy, aiming to provide a reliable systematic summary for novel therapies. Collectively, comprehensively dissects pioneering work Aβ-targeted insight into AD-modified Keywords: disease, amyloid-β, antibody, therapeutics, nanomedicine
Language: Английский
Citations
19
Molecules, Journal Year: 2024, Volume and Issue: 29(21), P. 5131 - 5131
Published: Oct. 30, 2024
The most prevalent chronic neurodegenerative illness in the world is Alzheimer's disease (AD). It results mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial psychological impact on relatives of patients. review discusses various pathophysiological mechanisms contributing to AD, amyloid beta, tau protein, inflammation, other factors, while emphasizing need for effective disease-modifying therapeutics that alter progression rather than merely alleviating symptoms. This mainly covers medications are now being studied clinical trials or recently approved by FDA fall under treatment (DMT) category, alters targeting underlying biological DMTs focus improving patient outcomes slowing decline, enhancing neuroprotection, supporting neurogenesis. Additionally, amyloid-targeting therapies, tau-targeting neuroprotective others. evaluation specifically looked at studies FDA-approved novel Phase II III development were carried out between 2021 2024. A thorough US government database identified biologics small molecule drugs 14 agents I, 34 II, 11 might be completed 2028.
Language: Английский
Citations
7
Drug Discovery Today, Journal Year: 2024, Volume and Issue: 29(5), P. 103974 - 103974
Published: March 29, 2024
Language: Английский
Citations
6
GeroScience, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 27, 2024
Language: Английский
Citations
6
BioScience Trends, Journal Year: 2023, Volume and Issue: 17(4), P. 283 - 292
Published: Aug. 22, 2023
Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions worldwide and expected to surge in prevalence due aging populations. Frailty, characterized by muscle function decline, becomes more prevalent with age, imposing substantial burdens on patients caregivers. This paper aimed comprehensively review the current literature AD coupled frailty, encompassing prevalence, screening, assessment, treatment while delving into field's challenges future trajectories. Frailty coexist than 30% of cases, hazard ratios above 120% indicating mutually detrimental association.Various screening tools have emerged for both frailty AD, including Fried Phenotype (FP), FRAIL scale, Edmonton Scale (EFS), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clock Drawing Test (CDT), General Practitioner Cognition (GPCOG). However, none has solidified its role as definitive gold standard. The convergence electronic health records brain biomarkers heralds new era assessment. In terms intervention, non-pharmacological strategies spanning nutrition, horticulture, exercise, social interaction, along pharmacological approaches involving acetylcholinesterase inhibitors (AChEIs), N-methyl-D-aspartate (NMDA) receptor antagonists, anti-amyloid beta-protein medications, constituted cornerstones treating frailty. Technological interventions like repetitive transcranial magnetic stimulation (rTMS) also entered fold. Notably, multi-domain wield considerable potential enhancing cognition mitigating disability. long-term efficacy safety necessitate further validation. Diagnosing managing present several daunting challenges, low rates early co-diagnosis, limited clinical trial evidence, scarce integrated, pioneering service delivery models. These demand heightened attention through robust research pragmatic implementation.
Language: Английский
Citations
15
Molecules, Journal Year: 2025, Volume and Issue: 30(4), P. 922 - 922
Published: Feb. 17, 2025
This study examines the intricacies of Alzheimer's disease (AD), its origins, and potential advantages various herbal extracts natural compounds for enhancing memory cognitive performance. Future studies into AD treatments are encouraged by review's demonstration effectiveness phytoconstituents that were extracted from a number plants. In addition to having many beneficial effects, such as improved cholinergic function, medicines also much less harmful, more readily available, easier use than other treatments. They pass without difficulty through blood-brain barrier (BBB). focused on substances their effects using academic databases identify peer-reviewed published between 2015 2024. According literature review, 66 isolated 21 distinct plants have shown efficacy, which could be encouraging future research therapies. Since most clinical trials produce contradictory results, suggests larger-scale with longer treatment durations necessary validate or refute therapeutic efficacy
Language: Английский
Citations
0